A large randomized trial has produced the first clear answer to a question millions of older adults and their doctors have argued over without evidence: whether starting a statin after age 70, in someone who has never had a heart attack or stroke, is worth doing.
The STAREE trial found that daily atorvastatin reduced major cardiovascular events by 30 percent compared with placebo in people aged 70 and older who had no known cardiovascular disease, diabetes or dementia. It did not improve disability free survival. Results were presented in a Hot Line session at the European Society of Cardiology Congress in Munich and published simultaneously in the New England Journal of Medicine.
The finding matters for ordinary households because this age group was largely written out of the trials that built statin guidelines in the first place. Adults over 70 and their adult children have been making this decision on extrapolated data. That is no longer the case.
The First Trial Built for This Age Group
STAREE enrolled 9,971 participants recruited from Australian general practice, randomly assigned in equal numbers to 40 mg of atorvastatin daily or placebo. The mean age was 74.7 years and 52 percent were women. Everyone entered without a history of clinical cardiovascular disease, diabetes, or dementia.
Over a median follow-up of 5.9 years, major cardiovascular events occurred in 6.0 percent of the atorvastatin group and 8.3 percent of the placebo group. That is the 30 percent relative reduction in the headline, and it corresponds to a difference of about 2.3 percentage points in absolute terms over roughly six years.
The composite endpoint counted cardiovascular death, nonfatal heart attack, stroke and coronary revascularization together. That combination is standard in cardiology trials, but it means the headline number should not be read as applying to any single one of those outcomes.
Benefit on Heart Events, Not on Independence
The trial had two primary endpoints, and the second one did not deliver. Disability free survival, defined as survival free of dementia and physical disability, showed no meaningful difference between groups. The combined rate of death, dementia, or persistent physical disability was 12.8 percent with atorvastatin and 13.6 percent with placebo, a gap that did not reach statistical significance.
That distinction deserves to sit near the top rather than at the bottom. For many families, the reason to consider a preventive medication at 75 is not simply avoiding a cardiac event but staying independent longer. On that measure, this trial did not show a benefit.
Both outcomes can be true at the same time. Fewer heart attacks, strokes and revascularization procedures is a real result with real consequences for hospital admissions, recovery time and caregiving demands. It is simply not the same claim as living longer in good health, and the trial did not support the broader claim.
Side Effects Worth Discussing with a Clinician
Adverse events were not absent. Muscle, liver, and diabetes related adverse events were more frequent in the atorvastatin group. Serious adverse events overall were uncommon and occurred at the same rate in both arms, in 2.7 percent of participants.
Those tradeoffs land differently depending on the person. Older adults already taking several prescriptions face compounding considerations. The National Institute on Aging notes in its analysis of polypharmacy and deprescribing that inappropriate use of excessive or unnecessary medications raises the risk of adverse drug effects, harmful drug interactions, and situations in which a medication prescribed for one condition worsens another. The agency also cites federal data showing about one third of adults in their 60s and 70s used five or more prescription drugs in a 30 day period.
Adding an eighth or ninth daily medication is a different proposition from adding a second. So is adding one to a person with limited life expectancy, significant frailty, or difficulty affording and managing prescriptions. None of those situations were the focus of this trial.
Nobody should start, stop, or change a statin based on a news report. This is a conversation for a clinician who knows the full medication list.
Conversations Guidelines May Soon Reflect
The trial was funded by Australia's National Health and Medical Research Council and the Heart Foundation of Australia, both public and nonprofit funders rather than a drug manufacturer. Professor Sophia Zoungas of the Monash University School of Public Health and Preventive Medicine, who led the research, disclosed funding as principal investigator and payments to Monash University from several pharmaceutical companies for consultancy work outside the submitted study.
Two limits on generalizability are worth naming. The participants were recruited from Australian general practice, and people with diabetes or dementia were excluded by design, which removes two very common conditions from the picture. Whether the result transfers cleanly to a 78-year-old American with diabetes and four other prescriptions is not something this trial answers.
Guidelines have not changed. "We hope to see updated guidelines to help clinicians make use of these new findings," Zoungas said. The European Society of Cardiology, which hosted the congress where results were presented, is among the bodies that periodically revise cholesterol guidance through its clinical practice guidelines process. U.S. guideline groups will review the published paper on their own timelines, and no revision date has been announced.
For now, older adults who already take a statin should keep taking it unless a clinician advises otherwise. Those who do not take one and are curious can bring the trial up at their next appointment, along with their blood pressure readings, current medication list, and any history of muscle symptoms, which sit alongside cholesterol in standard risk factors and prevention assessment. The strongest version of this conversation includes what the person actually wants out of the next decade.
Key Questions Answered
What did the trial find? Atorvastatin 40 mg daily reduced major cardiovascular events by 30 percent relative to placebo, with rates of 6.0 percent versus 8.3 percent over a median of 5.9 years.
Who was studied? A total of 9,971 adults aged 70 and older recruited from Australian general practice, with no known cardiovascular disease, diabetes or dementia.
Did the statin help people stay independent? No. Disability free survival showed no significant difference between the two groups.
What side effects were seen? Muscle, liver, and diabetes related adverse events were more frequent with atorvastatin. Serious adverse events were uncommon and equal in both groups at 2.7 percent.
Do current guidelines change because of this? Not yet. The researchers said they hope guidelines will be updated, but no guideline body has issued a revision.
Should someone over 70 start a statin now? That is a decision for a clinician who knows the person's full medication list, other conditions, and personal goals.
Who funded the research? Australia's National Health and Medical Research Council and the Heart Foundation of Australia.
